NCT00364546View on ClinicalTrials.gov

A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain

PHASE3CompletedINTERVENTIONAL

Enrollment

877

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

July 31, 2007

Conditions

OsteoarthritisPain Intensity AssessmentArthralgiaSciaticaLow Back Pain

Interventions

DRUG

CG 5503;tapentadol

Sponsors

Collaborators (1)

Grünenthal GmbH

All Listed Sponsors

collaborator

Grünenthal GmbH

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY